Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TroVax plus Docetaxel in HRPC
NCT00521274Phase 2Terminated
- Sponsor
- Houston Methodist Research Institute
- Start
- Aug 2007
- Primary completion
- Jul 2008
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MVA-5T4 in prostate cancer (PCa) (2 arms), sponsored by Houston Methodist Research Institute. Primary endpoints: Time to PSA progression and Safety (Adverse Events, Lab Measurements, Vital Signs). Started Aug 2007; status: terminated.
02
Drugs
MVA-5T4
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00521274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00521274.